Gain Therapeutics Inc GANX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.82
- Day Range
- $1.74–1.82
- 52-Week Range
- $1.41–4.34
- Bid/Ask
- $1.80 / $1.83
- Shares Outstanding
- 42.65M
- Market Cap
- $76.78M
- Volume/Avg
- 610,222 / 845,689
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 21
- Website
- https://www.gaintherapeutics.com
Valuation
|
Metric
|
GANX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.49 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GANX
|
|---|---|
Quick Ratio | 4.51 |
Current Ratio | 4.69 |
Interest Coverage | — |
Quick Ratio
GANX
Profitability
|
Metric
|
GANX
|
|---|---|
Return on Assets (Normalized) | −134.00% |
Return on Equity (Normalized) | −206.73% |
Return on Invested Capital (Normalized) | −195.72% |
Return on Assets
GANX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sT@pxQT | LOCK|^q?X | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|hT<@#> | LOCK|g>rJc | $70B | |||
| argenx SE ADR
ARGX
| LOCK|gR?d?Yk | LOCK|wN$ | $57B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&y@!?n | LOCK|LGT< | $42B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%wqz<Q | LOCK|<r | $35B | |||
| Moderna Inc
MRNA
| LOCK|zMB#@X | LOCK|Q$ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|gyrgMt#P | LOCK|rSFZ | $26B | |||
| Incyte Corp
INCY
| LOCK|y!fZT^x | LOCK|w& | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|$K%jnD | LOCK|^zW | $24B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|x!!!!mv | LOCK|<B | $18B |
United States